MCID: PRM014
MIFTS: 39

Periampullary Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Periampullary Adenocarcinoma

MalaCards integrated aliases for Periampullary Adenocarcinoma:

Name: Periampullary Adenocarcinoma 12 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:8110
NCIt 50 C27322
UMLS 70 C1335377

Summaries for Periampullary Adenocarcinoma

MalaCards based summary : Periampullary Adenocarcinoma is related to cholangiocarcinoma and adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Periampullary Adenocarcinoma is SATB1 (SATB Homeobox 1), and among its related pathways/superpathways are IL-2 Pathway and PI3K-Akt signaling pathway. The drugs Oxaliplatin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and pancreas, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Periampullary Adenocarcinoma

Diseases related to Periampullary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 29.8 ERBB2 EGFR CDKN1B
2 adenocarcinoma 29.7 ERBB3 ERBB2 EGFR CDKN1B CCND1
3 intrahepatic cholangiocarcinoma 29.5 ERBB2 EGFR CCND1
4 bile duct cancer 29.5 ERBB2 EGFR CCND1
5 pancreatic adenocarcinoma 29.4 ERBB3 ERBB2 EGFR CDKN1B CCND1
6 pancreatic cancer 28.9 SLC29A1 ERBB3 ERBB2 EGFR DCK CDKN1B
7 squamous blepharitis 10.3 ERBB3 EGFR
8 breast scirrhous carcinoma 10.2 ERBB2 EGFR
9 mixed cell adenoma 10.2 ERBB3 EGFR
10 breast metaplastic carcinoma 10.2 ERBB2 EGFR
11 submandibular gland cancer 10.2 ERBB2 EGFR
12 breast malignant phyllodes tumor 10.2 ERBB2 EGFR
13 progesterone-receptor negative breast cancer 10.2 ERBB2 EGFR
14 apocrine adenocarcinoma 10.2 ERBB2 EGFR
15 biliary tract cancer 10.2 ERBB2 EGFR
16 primary peritoneal carcinoma 10.2 ERBB2 EGFR
17 microglandular adenosis 10.2 ERBB2 EGFR
18 lung non-squamous non-small cell carcinoma 10.2 ERBB2 EGFR
19 pancreatic ductal adenocarcinoma 10.1
20 neurofibromatosis 10.1
21 gastroesophageal junction adenocarcinoma 10.1 ERBB2 EGFR
22 vulvar disease 10.1 ERBB2 EGFR
23 vallecula cancer 10.1 ERBB3 CDKN1B
24 placental site trophoblastic tumor 10.1 ERBB2 EGFR
25 glass syndrome 10.1 SATB2 SATB1
26 inflammatory breast carcinoma 10.1 ERBB2 EGFR
27 gallbladder adenocarcinoma 10.1 SLC29A1 ERBB2 EGFR
28 paronychia 10.1 ERBB3 ERBB2 EGFR
29 uterine carcinosarcoma 10.1 ERBB3 ERBB2 EGFR
30 uterine body mixed cancer 10.1 ERBB2 EGFR
31 papillary adenocarcinoma 10.1
32 obstructive jaundice 10.1
33 duodenum adenocarcinoma 10.1
34 duodenum cancer 10.1
35 gastrointestinal stromal tumor 10.1
36 keratoconjunctivitis sicca 10.1 ERBB3 ERBB2
37 gastroesophageal adenocarcinoma 10.0 ERBB2 EGFR
38 transitional cell carcinoma 10.0 ERBB3 ERBB2 EGFR
39 gallbladder cancer 10.0 ERBB3 ERBB2 EGFR
40 esophagus verrucous carcinoma 10.0 EGFR CCND1
41 mammary analogue secretory carcinoma 10.0 EGFR CCND1
42 tonsil cancer 10.0 ERBB2 EGFR CDKN1B
43 bone squamous cell carcinoma 9.9 EGFR CCND1
44 thoracic benign neoplasm 9.9 ERBB2 EGFR
45 breast papillomatosis 9.9 ERBB2 CCND1
46 signet ring cell adenocarcinoma 9.9
47 ampulla of vater adenocarcinoma 9.9
48 somatostatinoma 9.9
49 bile duct adenocarcinoma 9.9
50 distal biliary tract carcinoma 9.9

Graphical network of the top 20 diseases related to Periampullary Adenocarcinoma:



Diseases related to Periampullary Adenocarcinoma

Symptoms & Phenotypes for Periampullary Adenocarcinoma

UMLS symptoms related to Periampullary Adenocarcinoma:


abdominal pain

GenomeRNAi Phenotypes related to Periampullary Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.53 EGFR
2 Decreased viability GR00055-A-2 9.53 EGFR
3 Decreased viability GR00106-A-0 9.53 ERBB3
4 Decreased viability GR00107-A-1 9.53 DCK
5 Decreased viability GR00221-A-1 9.53 DCK EGFR
6 Decreased viability GR00221-A-2 9.53 DCK ERBB3
7 Decreased viability GR00221-A-3 9.53 ERBB2
8 Decreased viability GR00221-A-4 9.53 DCK EGFR ERBB2 ERBB3
9 Decreased viability GR00240-S-1 9.53 DCK
10 Decreased viability GR00301-A 9.53 ERBB3
11 Decreased viability GR00386-A-1 9.53 DCK

MGI Mouse Phenotypes related to Periampullary Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.08 CCND1 CDKN1B DCK EGFR ELAVL1 ERBB2
2 endocrine/exocrine gland MP:0005379 10.06 CCND1 CDKN1B DCK EGFR ELAVL1 ERBB2
3 digestive/alimentary MP:0005381 10.03 CCND1 CDKN1B EGFR ELAVL1 ERBB2 ERBB3
4 hematopoietic system MP:0005397 10.02 CCND1 CDKN1B DCK EGFR ELAVL1 PIGR
5 immune system MP:0005387 10.02 CCND1 CDKN1B DCK EGFR ELAVL1 ERBB3
6 craniofacial MP:0005382 9.93 CCND1 CDKN1B EGFR ELAVL1 ERBB2 SATB2
7 neoplasm MP:0002006 9.73 CCND1 CDKN1B EGFR ELAVL1 ERBB2 ERBB3
8 reproductive system MP:0005389 9.7 CCND1 CDKN1B EGFR ELAVL1 ERBB2 PIGR
9 respiratory system MP:0005388 9.5 CCND1 CDKN1B EGFR ELAVL1 ERBB2 ERBB3
10 skeleton MP:0005390 9.23 CCND1 CDKN1B EGFR ELAVL1 ERBB2 SATB1

Drugs & Therapeutics for Periampullary Adenocarcinoma

Drugs for Periampullary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 5310940 9887054 43805 6857599
2
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
3
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
4
Pancrelipase Approved, Investigational Phase 1 53608-75-6
5
Motexafin gadolinium Investigational Phase 1 246252-06-2, 156436-89-4 12047567
6
Erlotinib Hydrochloride Phase 1 183319-69-9 176871
7 Protein Kinase Inhibitors Phase 1
8 Liver Extracts Phase 1
9 Histone Deacetylase Inhibitors Phase 1
10 pancreatin Phase 1
11 Photosensitizing Agents Phase 1
12 Dermatologic Agents Phase 1
13
Gemcitabine Approved 95058-81-4 60750
14
Paclitaxel Approved, Vet_approved 33069-62-4 36314
15
Fluorouracil Approved 51-21-8 3385
16 Anti-Infective Agents
17 Immunosuppressive Agents
18 Antiviral Agents
19 Immunologic Factors
20 Antimetabolites
21 Tubulin Modulators
22 Antimitotic Agents
23 Albumin-Bound Paclitaxel
24 Folfirinox
25 Omega 3 Fatty Acid
26 Whey Protein
27
Arginine Investigational, Nutraceutical 74-79-3 6322

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma Adenocarcinoma Active, not recruiting NCT01781728 Phase 2
2 Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer. Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
3 Phase I Trial of Chemoradiation With Capecitabine and Vorinostat in Pancreatic Cancer. Completed NCT00983268 Phase 1 capecitabine;vorinostat
4 Phase I Study Involving Gadolinium Texaphyrin (NSC 695238) in Patients With Pancreatic and Periampullary Adenocarcinoma Receiving Radiotherapy for Unresectable Disease Completed NCT00003798 Phase 1 motexafin gadolinium
5 Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer Recruiting NCT03724994 Gemcitabine
6 The Pancreatic and Periampullary Resection Arginine Immunomodulation (PRIMe) Trial: A Randomized Phase II Trial of the Impact of Perioperative Immunomodulation on Immune Function Following Resection for Pancreatic or Periampullary Adenocarcinoma Not yet recruiting NCT04549662

Search NIH Clinical Center for Periampullary Adenocarcinoma

Genetic Tests for Periampullary Adenocarcinoma

Anatomical Context for Periampullary Adenocarcinoma

MalaCards organs/tissues related to Periampullary Adenocarcinoma:

40
Liver, Lymph Node, Pancreas, Endothelial

Publications for Periampullary Adenocarcinoma

Articles related to Periampullary Adenocarcinoma:

(show top 50) (show all 145)
# Title Authors PMID Year
1
Primary squamous cell carcinoma of the ampulla of Vater: management and review of the literature. 61
33414110 2021
2
Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma. 61
33471373 2021
3
Comparison of laparoscopic and open pancreaticoduodenectomy for the treatment of nonpancreatic periampullary adenocarcinomas: a propensity score matching analysis. 61
33386105 2020
4
Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy. 61
33227091 2020
5
Prognostic factors for long-term survival after pancreaticoduodenectomy for periampullary adenocarcinoma. A retrospective cohort study. 61
32874564 2020
6
Increased expression of secreted frizzled related protein 1 (SFRP1) predicts ampullary adenocarcinoma recurrence. 61
32764696 2020
7
Cap-assisted endoscopy increases ampulla of Vater visualization in high-risk patients. 61
32646369 2020
8
A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients. 61
32552660 2020
9
Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. 61
32129882 2020
10
Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study. 61
32293352 2020
11
Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma. 61
30216219 2020
12
Topographical Distribution and Spatial Interactions of Innate and Semi-Innate Immune Cells in Pancreatic and Other Periampullary Adenocarcinoma. 61
33013928 2020
13
Prognostic impact of tumor budding and EMT in periampullary adenocarcinoma: a quantitative approach. 61
33046968 2020
14
Pancreaticogastrostomy: A Safe Option in Pancreaticoduodenectomy for Pancreatic Head and Periampullary Neoplasms. 61
31931933 2020
15
Impact of Patient Age on Morbidity and Survival Following Laparoscopic Pancreaticoduodenectomy. 61
31107854 2019
16
Apparent diffusion coefficient-based histogram analysis differentiates histological subtypes of periampullary adenocarcinoma. 61
31686767 2019
17
Role of Immunohistochemistry in the Subtyping of Periampullary Adenocarcinoma. 61
30942099 2019
18
Four hundred fifty-three consecutive pancreaticoduodenectomies with pancreaticogastrostomy. 61
30563695 2019
19
Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combination. 61
31102323 2019
20
Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012. 61
30561818 2019
21
[Meta-analysis of adjuvant therapy for periampullary adenocarcinoma]. 61
30758617 2019
22
Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma. 61
31827798 2019
23
Mutational Landscape in Resected Periampullary Adenocarcinoma: Relationship With Morphology and Clinical Outcome. 61
32914025 2019
24
Metastasectomy of pancreatic and periampullary adenocarcinoma to solid organ: The current evidence. 61
30610789 2018
25
Predictors of long-term survival after pancreaticoduodenectomy for peri-ampullary adenocarcinoma: A retrospective study of 5-year survivors. 61
30126828 2018
26
The role of intraoperative radiotherapy (IORT) in the management of patients with pancreatic and periampullary cancer: A single center experience. 61
29680448 2018
27
Preoperative CT in patients with surgically resectable pancreatic adenocarcinoma: does the time interval between CT and surgery affect survival? 61
28695235 2018
28
Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. 61
29540182 2018
29
Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy. 61
29580215 2018
30
Comparison of Laparoscopic and Open Pancreaticoduodenectomy for the Treatment of Nonpancreatic Periampullary Adenocarcinomas. 61
29334528 2018
31
Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas. 61
29723245 2018
32
Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. 61
29556579 2018
33
Surgical management of periampullary adenocarcinoma: defining an optimal prognostic lymph node stratification schema. 61
29760806 2018
34
Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification. 61
29464064 2018
35
[Meta-analysis of adjuvant therapy for periampullary adenocarcinoma]. 61
28871347 2017
36
Role of adjuvant chemotherapy in T2N0M0 periampullary cancers. 61
28029222 2017
37
The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype. 61
28673320 2017
38
Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. 61
28518410 2017
39
Immunohistochemical expression of CDX2, CK7, HER2 and HER4 in periampullary adenocarcinoma : implications for clinicopathology and patient outcomes. 61
29364095 2017
40
Solitary Skull Metastasis as the First Presentation of a Metachronous Primary Lung Cancer in a Survivor from Pancreatic Cancer. 61
28811947 2017
41
Distinguishing Benign from Malignant Pancreatic and Periampullary Lesions Using Combined Use of ¹H-NMR Spectroscopy and Gas Chromatography-Mass Spectrometry. 61
28098776 2017
42
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma. 61
27488532 2016
43
Clinical outcomes of pancreaticoduodenectomy in octogenarians: a surgeon's experience from 2007 to 2015. 61
27563443 2016
44
Efficacy of Multidetector-Row Computed Tomography as a Practical Tool in Comparison to Invasive Procedures for Visualization of the Biliary Obstruction. 61
27708488 2016
45
Oncologic and Perioperative Outcomes Following Selective Application of Laparoscopic Pancreaticoduodenectomy for Periampullary Malignancies. 61
27142633 2016
46
Successful Experience of Laparoscopic Pancreaticoduodenectomy and Digestive Tract Reconstruction With Minimized Complications Rate by 14 Case Reports. 61
27124014 2016
47
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma. 61
26590090 2016
48
The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. 61
27275582 2016
49
Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. 61
27070783 2016
50
Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. 61
26362587 2016

Variations for Periampullary Adenocarcinoma

Expression for Periampullary Adenocarcinoma

Search GEO for disease gene expression data for Periampullary Adenocarcinoma.

Pathways for Periampullary Adenocarcinoma

Pathways related to Periampullary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 ERBB3 ERBB2 EGFR CDKN1B CCND1
2
Show member pathways
12.79 ERBB3 ERBB2 EGFR CDKN1B CCND1
3
Show member pathways
12.71 ERBB2 EGFR CDKN1B CCND1
4 12.68 ERBB2 EGFR CDKN1B CCND1
5
Show member pathways
12.61 ERBB2 EGFR CDKN1B CCND1
6
Show member pathways
12.57 ERBB3 ERBB2 EGFR CDKN1B
7
Show member pathways
12.4 ERBB3 ERBB2 EGFR CDKN1B CCND1
8
Show member pathways
12.27 ERBB3 ERBB2 EGFR CDKN1B CCND1
9
Show member pathways
12.19 ERBB3 ERBB2 EGFR
10
Show member pathways
12.14 ERBB3 ERBB2 EGFR
11
Show member pathways
12.1 ERBB3 ERBB2 EGFR CCND1
12 12.07 ERBB3 ERBB2 EGFR CCND1
13 12 PIGR EGFR CCND1
14 11.98 ERBB3 ERBB2 EGFR
15
Show member pathways
11.94 EGFR CDKN1B CCND1
16
Show member pathways
11.89 ERBB3 ERBB2 EGFR
17 11.87 EGFR CDKN1B CCND1
18 11.85 ERBB3 ERBB2 EGFR CDKN1B CCND1
19 11.84 ERBB2 CDKN1B CCND1
20
Show member pathways
11.84 ERBB3 ERBB2 EGFR CDKN1B CCND1
21 11.82 EGFR CDKN1B CCND1
22 11.8 ERBB2 EGFR CDKN1B
23
Show member pathways
11.79 ERBB3 ERBB2 EGFR
24 11.69 DCK CDKN1B CCND1
25 11.59 ERBB2 EGFR CCND1
26 11.54 ERBB2 EGFR CDKN1B
27 11.52 EGFR CDKN1B CCND1
28 11.47 ERBB2 CDKN1B CCND1
29 11.43 ERBB3 ERBB2 EGFR
30 11.26 ERBB3 ERBB2 EGFR
31
Show member pathways
11.15 ERBB2 EGFR CDKN1B CCND1
32 11.14 ERBB2 EGFR
33
Show member pathways
11.14 ERBB3 ERBB2 EGFR CDKN1B CCND1
34 11.04 ERBB3 ERBB2 EGFR
35 10.66 SLC29A1 DCK

GO Terms for Periampullary Adenocarcinoma

Cellular components related to Periampullary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.62 SLC29A1 ERBB3 ERBB2 EGFR
2 basolateral plasma membrane GO:0016323 9.56 SLC29A1 ERBB3 ERBB2 EGFR
3 receptor complex GO:0043235 9.46 PIGR ERBB3 ERBB2 EGFR
4 basal plasma membrane GO:0009925 9.13 ERBB3 ERBB2 EGFR
5 ERBB3:ERBB2 complex GO:0038143 8.62 ERBB3 ERBB2

Biological processes related to Periampullary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.83 ERBB3 ERBB2 EGFR DCK CDKN1B
2 positive regulation of protein phosphorylation GO:0001934 9.75 ERBB2 EGFR CCND1
3 positive regulation of cell proliferation GO:0008284 9.72 ERBB3 ERBB2 EGFR CDKN1B CCND1
4 positive regulation of protein kinase B signaling GO:0051897 9.71 ERBB3 ERBB2 EGFR
5 peptidyl-tyrosine phosphorylation GO:0018108 9.7 ERBB3 ERBB2 EGFR
6 response to organic cyclic compound GO:0014070 9.69 EGFR CDKN1B CCND1
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 ERBB3 ERBB2 EGFR
8 response to estradiol GO:0032355 9.65 EGFR CDKN1B CCND1
9 wound healing GO:0042060 9.63 ERBB3 ERBB2 EGFR
10 positive regulation of kinase activity GO:0033674 9.58 ERBB3 ERBB2 EGFR
11 regulation of ERK1 and ERK2 cascade GO:0070372 9.57 ERBB2 EGFR
12 cellular response to organic substance GO:0071310 9.56 SATB2 CCND1
13 peripheral nervous system development GO:0007422 9.55 ERBB3 ERBB2
14 negative regulation of ERBB signaling pathway GO:1901185 9.37 ERBB2 EGFR
15 regulation of cell motility GO:2000145 9.33 ERBB3 ERBB2 EGFR
16 response to UV-A GO:0070141 9.26 EGFR CCND1
17 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.13 EGFR CDKN1B CCND1
18 ERBB2 signaling pathway GO:0038128 8.8 ERBB3 ERBB2 EGFR

Molecular functions related to Periampullary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.73 ERBB3 ERBB2 EGFR CCND1
2 protein kinase binding GO:0019901 9.71 ELAVL1 EGFR CDKN1B CCND1
3 transmembrane signaling receptor activity GO:0004888 9.56 PIGR ERBB3 ERBB2 EGFR
4 protein tyrosine kinase activity GO:0004713 9.54 ERBB3 ERBB2 EGFR
5 protein phosphatase binding GO:0019903 9.5 ERBB2 EGFR CDKN1B
6 ErbB-3 class receptor binding GO:0043125 9.16 ERBB3 ERBB2
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 ERBB3 ERBB2 EGFR
8 kinase activity GO:0016301 9.1 ERBB3 ERBB2 EGFR DCK CDKN1B CCND1

Sources for Periampullary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....